Favorites and recent references stay on this device. No patient data is stored.
Choose the species
One selection filters the source overview, clinical facts, reports and dose calculator. Literature references are not species-filtered.
Choose one species for its overview and dose calculator, or all species to browse the full evidence.
Source overview
Recorded excerpts for one species. Each dose remains a separate source entry; no regimen is selected.
No clinical assertions recorded for an overview.
View full clinical evidence and sources ↓Clinical evidence
Dose regimens0
No dose regimens recorded for this species selection.
Adverse effects105
These are counts of spontaneously reported events, not proven adverse effects, causal relationships, or incidence rates.
Bars compare report counts within each species; they do not show incidence.
More reportsFewer reportsDog
- Lack of efficacy - NOS321 reports
- Lethargy (see also Central nervous system depression in Neurological)230 reports
- Diarrhoea196 reports
- Vomiting169 reports
- Neutropenia168 reports
- Decreased haematocrit132 reports
- Elevated serum alkaline phosphatase (ALP)119 reports
- Lymphopenia113 reports
- Elevated alanine aminotransferase (ALT)99 reports
- Leucopenia NOS97 reports
- Other abnormal test result NOS93 reports
- Anaemia NOS90 reports
Cat
- Accidental exposure1 reports
- Distress1 reports
- Elevated temperature1 reports
- Increased heart rate1 reports
- Increased respiratory rate1 reports
Literature references8
References are linked to this drug. Species applicability is not recorded here, so the species filter does not narrow this list. Imported dates do not retain their original precision; confirm dates in the original citation.
- Anti-Cytokine Drugs in the Treatment of Canine Atopic Dermatitis.
Study summary not available in the imported record. Open the original citation to review the study.
- Pharmacokinetics of Ilunocitinib, a New Janus Kinase Inhibitor, in Dogs.
Study summary not available in the imported record. Open the original citation to review the study.
- Efficacy and Field Safety of Ilunocitinib for the Control of Allergic Dermatitis in Client-Owned Dogs: A Multicenter, Double-Masked, Randomised, Placebo-Controlled Clinical Trial.
Study summary not available in the imported record. Open the original citation to review the study.
- Immunologic response to first booster vaccination in dogs treated with zenrelia™ (ilunocitinib tablets) at up to three times the recommended therapeutic dose compared to untreated controls.
Study summary not available in the imported record. Open the original citation to review the study.
- Response to primary canine core vaccination in 10-month-old seronegative dogs treated with three times the recommended therapeutic dose of Ilunocitinib tablets (Zenrelia™).
Study summary not available in the imported record. Open the original citation to review the study.
Sources: PubMed, National Library of Medicine; openFDA, U.S. Food and Drug Administration.
Available products
Products listed in the Health Canada Drug Product Database for this active ingredient. A listing does not establish that a product is authorized for the clinical uses described on this page.